Allarity Therapeutics, Inc. ALLR
0.95 USD +0.02 (+2.12%)
Nov 13, 2026, 1:08 PM EST
0.88 Day range 0.9848
0.769 52-week range 1.84
- YTD
- -12.42%
- 1 year
- -20.51%
News
benzinga.com Allarity Therapeutics Q3 EPS $(0.39) Misses $(0.21) Estimate, Sales $5.000K Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.21) by 85.71 percent. This is a 105.26 percent decrease over…
globenewswire.com Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance - Ended third quarter with $24.1 million in cash and restricted cash - Expects positive fourth quarter earnings between $0.01 and $0.04 per share
benzinga.com Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an
benzinga.com Allarity Therapeutics Terminates $6M Equity Purchase Agreement With Tumim Stone Capital To Pursue Alternative Financing; Says No Early Termination Penalty Is Payable -SEC Filing
benzinga.com Allarity Therapeutics Receives First Contract For Its Development, Validation And Related Laboratory Services From Undisclosed European Biotech Firm Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT- benzinga.com Allarity Therapeutics Highlights DRP Technology, Patent And Lab Advances To Support Stenoparib Development And Partnerships Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT
benzinga.com Allarity Therapeutics Expands Capabilities Of Its In-House Medical Laboratory To Include Proteomics And Cell Line Research - Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib- New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable…
benzinga.com Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
benzinga.com Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
benzinga.com Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11 Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.- benzinga.com Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 40 percent decrease over losses of…
- benzinga.com Allarity Therapeutics Secures CLIA For In-House Lab Allarity Therapeutics is now poised to run its DRP® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials must…
- benzinga.com Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ:ALLR) stock…
benzinga.com Allarity Therapeutics To Present A Trial-In-Progress Poster At The ESMO Gynaecological Cancers Congress, June 17–19 The poster outlines the scientific background, study design, and clinical rationale for the Company's ongoing Phase 2 trial evaluating stenoparib in patients with advanced platinum-resistant or…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25 Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.75 to $10.25.- benzinga.com Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of…
- benzinga.com Allarity Therapeutics Says API Manufacturing Campaign For Stenoparib Is Progressing In Line With Planned Timeline For Completion No Later Than Q3 Of 2026 At CDMO Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer Supports accelerating stenoparib toward FDA…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Crude Oil Down 2%; US Durable Goods Orders Decline In July 
benzinga.com US Stocks Mixed; American Woodmark Posts Downbeat Sales 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major benchmark indices were mixed in premarket trading. President Donald Trump‘s…
benzinga.com XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- benzinga.com Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.
- benzinga.com Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of…
- benzinga.com Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket Shares of Reliance Global Group, Inc. (NASDAQ: RELI) fell sharply in today’s pre-market trading after reporting financial results for the year ended Dec 31, 2023.
- benzinga.com Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.
- benzinga.com Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 369 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 169 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 225 companies set new 52-week lows.